Positron emission tomography (PET): experience with a large-field-of-view three-dimensional PET scanner

Hicks, Rodney J; Binns, David S; Fawcett, Meagan E; Ware, Robert E; Kalff, Victor; McKenzie, Allan F; Zalcberg, John P; Peters, Lester J

Topics

Neoplasms

Diagnostic techniques and procedures

Positron emission tomography (PET): experience with a large-field-of-view three-dimensional PET scanner

Correspondence:

1.
Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314: 884-888.
2.
Engel J, Henry TR, Risinger MW, et al. Presurgical evaluation for partial epilepsy: relative contributions of chronic depth-electrode recordings versus FDG-PET and scalp-sphenoidal ictal EEG. Neurology 1990; 40: 1670-1677.
3.
Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641-1674.
4.
Price P, Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? Eur J Cancer 1995; 31A: 1924-1927.
5.
Valk P, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995; 60: 1573-1582.
6.
Coleman RE. PET in lung cancer. J Nucl Med 1999; 40: 814-820.
7.
Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node sampling. Radiology 1997; 202: 441-446.
8.
Steinert HC, Huch BÖni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 195: 705-709.
9.
Delbeke D. Oncological application of FDG PET imaging; brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med 1999; 40: 591-603.
10.
Benchaou M, Lehman W, Slosman DO, et al. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. Acta Otolaryngol 1996; 116: 332-335.
11.
Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190: 111-116.
12.
Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 343-348.
13.
Tse NY, Hoh CK, Hawkins RA, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992; 216: 27-34.
14.
Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996; 23: 1588-1593.
15.
Avril N, Bense S, Ziegler SI, et al. Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med 1997; 38: 1186-1191.
16.
Kalff V, Hicks RJ, MacManus M, et al. The clinical impact of PET scanning in patients with lung cancer: a prospective study [Abstract]. J Nucl Med 1998; 39: 249.
17.
Hicks RJ, Kalff V, Binns DS, et al. Are high dose Ga-67 scans as good as FDG PET in staging melanoma? [Abstract] J Nucl Med 1998; 39: 11.
18.
Porceddu S, Hicks RJ, Rischin D, Peters L. Impact of PET on head and neck cancer. Proceedings of the 49th Annual Scientific Meeting of the Royal Australasian College of Radiology, 1998 Oct; Brisbane, Australia. [Abstract]: 290-291.
19.
Kalff V, Binns DS, Fawcett ME, Hicks RJ. Clinical impact of FDG PET scanning in colon cancer: a prospective study. Nucl Med Commun 1999; 20: 381.
20.
Murphy M, O'Brien TJ, Hicks RJ, et al. Experience of a 3-D, large-field-of-view PET scanner for the localisation of partial epilepsy. Annual Meeting of the American Epilepsy Society, 1999. Epilepsia (Suppl). In press.
21.
Strauss LG, Conti PS. The applications of PET in oncology. J Nucl Med 1991; 32: 623-648.
22.
Dewan NA, Reeb SD, Gupta N, et al. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions: a comparative risk- benefit analysis. Chest 1995; 108: 441-446.
23.
Gambhir SS, Hoh CK, Phelps ME, et al. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996; 37: 1428-1436.
24.
Lewis P, Griffin S, Marsden P, et al. Whole body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994; 344: 1265-1266.
25.
Karp JS, Muehllehner G, Mankoff DA, et al. Continuous-slice PENN-PET: a positron tomograph with volume imaging capability. J Nucl Med 1990; 31: 617-627.

Online responses are no longer available. Please refer to our instructions for authors page for more information.